drugset / Trial / NCT01242943
Radioimmunotherapy With 131I-L19SIP in Patients With Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The aim of this Study Protocol is to provide a basis for the clinical development of 131I-L19SIP as an anti-cancer therapeutic agent, following the promising results of a Phase I study.
Timeline
- Start
- 2008-11
- Primary completion
- 2011-02
- Completion
- 2011-05
Outcome
Outcome not reported
Stopped: “With the determination of the RD and a well established understanding of the safety and tolerability profile, the main endpoints of the study have been met.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 131I-L19SIP | Monoclonal antibody | 111 unknown | Intravenous |
| Subject | 131I-L19SIP | Monoclonal antibody | 139 unknown | Intravenous |
| Subject | 131I-L19SIP | Monoclonal antibody | 167 unknown | Intravenous |
Indications
No indication recorded.